Jonas Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-12-2024
- Paid Up Capital ₹ 0.10 M
as on 07-12-2024
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
About Jonas Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Arun Walia and Avi Walia serve as directors at the Company.
- CIN/LLPIN
U24232HR2014PTC051994
- Company No.
051994
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Feb 2014
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Jonas Pharmaceuticals Private Limited offer?
Jonas Pharmaceuticals Private Limited offers a wide range of products and services, including Mineral Supplement, Calcium Syrup, Antihistamines, Phenylephrine Hcl Tablet, Diclofenac, Diclofenac Paracetamol Tablet, Antibacterial Drugs, Levofloxacin Tablets, Antibiotic Injection, Ceftriaxone Injection.
Who are the key members and board of directors at Jonas Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Walia  | Director | 20-Mar-2017 | Current |
| Avi Walia | Director | 28-Jun-2023 | Current |
Financial Performance of Jonas Pharmaceuticals.
Jonas Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Jonas Pharmaceuticals?
In 2017, Jonas Pharmaceuticals had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aviotic Healthcare Private LimitedActive 6 years 7 monthsArun Walia and Avi Walia are mutual person
Jonas Lifesciences Private LimitedActive 6 years 7 monthsArun Walia and Avi Walia are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jonas Pharmaceuticals?
Unlock and access historical data on people associated with Jonas Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jonas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jonas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
